Blue Water Vaccines (BWV) will attempt to present monkeypox antigens within its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform to develop a novel monkeypox vaccine.

There is a need of better markers that reflect key mechanisms involved in diabetic kidney disease (DKD). In a new study, investigators have identified increased concentrations of neuroblastoma suppressor of tumorigenicity 1 (NBL1) as a strong and independent predictor of progression to end-stage kidney disease (ESKD) in patients with diabetes.

Preclinical data has been reported for RCD-405, which is being developed by Arcede Pharma, a spin-out from Respiratorius AB, for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD).

Stinging nettle leaf has been used in traditional treatments for conditions such as lower urinary tract symptoms, possibly through a smooth muscle relaxant effect. Monash University scientists have investigated the mechanism in studies in vitro and in vivo.

The U.S. Department of Defense (DoD) is awarding Codagenix USD 4.4 million for further development of its next-generation tetravalent dengue vaccine candidate CodaVax-DENV.

Hepatocellular carcinoma (HCC) still remains a global health challenge as it shows genetic heterogeneity and limited therapy response. In a new study, the cellular responses in HCC that accompany the nearly universal repression of urea cycle enzymes and consequent arginine auxotrophy were investigated, since previous findings demonstrated that that HCC consistently represses urea cycle gene expression and thus become auxotrophic for exogenous arginine becoming severe disease.

Merck & Co. is to collaborate with Orna Therapeutics on discovery, development and commercialization in multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology.

Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) has patented thiazolopyrimidones acting as discoidin domain-containing receptor 1 (DDR1) and/or DDR2 inhibitors reported to be useful for the treatment of atherosclerosis, cancer, cirrhosis, hepatic fibrosis, pulmonary fibrosis, lupus nephritis, osteoarthritis and rheumatoid arthritis, among others.

Ascentage Pharma has divulged spirocyclic indenes acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.

Sunshine Lake Pharma has synthesized amide pyrrole compounds reported to be useful for the treatment of liver cancer, cirrhosis and hepatitis B virus (HBV) infection.